Over 160 therapeutic and in vivo diagnostic monoclonal antibodies have been approved by
the US FDA since the first monoclonal antibody, muromonab, was approved in 1986 …

Highlights•More than 100 new experimental antibodies now enter into development each
year.•Half of experimental monoclonal antibodies and a third of approvals are potential …

Monoclonal antibodies (mAbs) comprise the majority of protein candidates currently in
clinical development because of their versatility as therapeutic agents. While traditionally …

Cancer is the second leading cause of death in the United States with one of every four
deaths attributable to cancer (Jemal et al. 2006). The first references to cancer date back to …

An increasing number of monoclonal antibodies for cancer diagnosis and treatment are in
clinical use and in the development pipeline, with more expected as new molecular targets …

Since the first monoclonal antibody, muromonab-CD3, was approved for therapeutic use in
1986, numerous molecules have been targeted using therapeutic antibody technology …

Over the last three decades, monoclonal antibodies have made a dramatic transformation
from scientific tools to powerful human therapeutics. At present, approximately 30 …

A large number of monoclonal antibodies (mAbs) are currently under investigation for the
treatment of malignant diseases. To date, a significant amount of experimental and clinical …

Monoclonal antibodies (mAbs) are a well established class of therapeutics as evidenced by
a large number of FDA approved mAbs for the treatment of cancers and autoimmune …

With the rapid growth of monoclonal antibody-based products, new technologies have
emerged for creating modified forms of antibodies, including fragments, conjugates and …